Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Curr Oncol Rep ; 24(12): 1863-1872, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36336769

RESUMO

PURPOSE OF REVIEW: The purpose of our paper is to describe the all-encompassing supportive care for patients with relapsed or refractory lymphoma undergoing cellular therapy, with a focus on the advanced practice provider's (APPs) perspective. RECENT FINDINGS: Chimeric antigen receptor-T (CAR-T) cell therapy has become more available for treating relapsed or refractory B-cell hematologic malignancies, requiring proficient and adequate treatment of side effects, complications, and infections that may occur during therapy. APPs often meet these patients during the initial referral and help to support them through the CAR-T cell therapy process. As APPs acquire a complete understanding and comprehensive knowledge of how to treat, support, and guide patients with B-cell malignancies through CAR-T cell therapy, they play a pivotal role in these patients throughout their treatment. Standardization of supportive care is paramount.


Assuntos
Neoplasias Hematológicas , Linfoma , Receptores de Antígenos Quiméricos , Humanos , Antígenos CD19 , Receptores de Antígenos de Linfócitos T , Imunoterapia Adotiva/efeitos adversos , Neoplasias Hematológicas/terapia , Terapia Baseada em Transplante de Células e Tecidos
2.
Curr Hematol Malig Rep ; 17(6): 243-253, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36117228

RESUMO

PURPOSE OF REVIEW: Acute myeloid leukemia (AML) survivors face unique challenges affecting long-term outcomes and quality of life. There is scant literature on the long-term impact of AML treatment in physical and mental health, disease recurrence, and financial burden in survivors. RECENT FINDINGS: Fatigue, mental health concerns, infections, sexual dysfunction, and increase cancer recurrence occur after AML treatment. Chronic graft-versus-host disease (GVHD) and infections are common concerns in AML after hematopoietic stem cell transplantation (HCT). Survivorship guidelines encompass symptoms and complications but fail to provide an individualized care plan for AML survivors. Studies in patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are sparse. Here we discuss the most common aspects pertaining to AML survivorship, late complications, care delivery, prevention of disease recurrence, and potential areas for implementation.


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda , Adulto , Humanos , Condicionamento Pré-Transplante/efeitos adversos , Sobrevivência , Qualidade de Vida/psicologia , Leucemia Mieloide Aguda/terapia , Leucemia Mieloide Aguda/complicações , Doença Enxerto-Hospedeiro/etiologia , Doença Enxerto-Hospedeiro/prevenção & controle , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Recidiva
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA